MCID: URN010
MIFTS: 55

Urinary Tract Obstruction

Categories: Nephrological diseases

Aliases & Classifications for Urinary Tract Obstruction

MalaCards integrated aliases for Urinary Tract Obstruction:

Name: Urinary Tract Obstruction 12 15 17 71
Obstructive Uropathy 12 54 15
Urinary Obstruction 12
Urologic Diseases 71

Classifications:



External Ids:

Disease Ontology 12 DOID:5200
ICD9CM 34 599.6
NCIt 49 C79805
SNOMED-CT 67 7163005
ICD10 32 N13.9
UMLS 71 C0042075 C0178879

Summaries for Urinary Tract Obstruction

MalaCards based summary : Urinary Tract Obstruction, also known as obstructive uropathy, is related to obstructive nephropathy and ureteral obstruction, and has symptoms including dysuria, polyuria and urgency of micturition. An important gene associated with Urinary Tract Obstruction is BNC2 (Basonuclin 2), and among its related pathways/superpathways are p70S6K Signaling and Pathways in cancer. The drugs Angiotensin II and Alfuzosin have been mentioned in the context of this disorder. Affiliated tissues include kidney, prostate and testes, and related phenotypes are growth/size/body region and cardiovascular system

Related Diseases for Urinary Tract Obstruction

Diseases related to Urinary Tract Obstruction via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 486)
# Related Disease Score Top Affiliating Genes
1 obstructive nephropathy 33.1 TGFB1 REN EGF CCL2 ALB
2 ureteral obstruction 31.5 TGFB1 PTGS2 AQP2
3 posterior urethral valves 31.5 TGFB1 BNC2
4 congenital anomalies of kidney and urinary tract 2 31.3 UMOD TGFB1 REN
5 chronic pyelonephritis 31.2 UMOD REN B2M ALB
6 interstitial cystitis 31.2 UMOD HBEGF EGF
7 acute cystitis 31.1 UMOD REN KLK3 CCL2 ALB
8 hydronephrosis 31.0 TGFB1 REN NAGLU MIR192 KLK3 EGF
9 renal hypertension 31.0 REN FN1 ALB
10 hyperuricemia 30.9 UMOD REN GGT1 ALB
11 acute kidney failure 30.9 UMOD REN EGF B2M ALB
12 pyelitis 30.8 UMOD REN B2M ALB
13 adenocarcinoma 30.8 TGFB1 PTGS2 PIK3CA KLK3 EGF
14 cystitis 30.8 UMOD PTGS2 HBEGF GDNF EGF CCL2
15 schistosomiasis 30.8 GGT1 CCL2 ALB
16 nephrolithiasis 30.7 UMOD GGT1 FN1 B2M ALB
17 glomerulonephritis 30.7 TGFB1 FN1 CCL2 B2M ALB
18 bacteriuria 30.6 UMOD CCL2 ALB
19 vesicoureteral reflux 1 30.6 UMOD TGFB1 REN NAGLU GDNF B2M
20 cakut 30.6 UMOD REN GDNF
21 gout 30.6 UMOD PTGS2 CCL2 ALB
22 gastroesophageal reflux 30.6 TGFB1 PTGS2 EGF CCL2
23 chronic kidney disease 30.6 UMOD TGFB1 REN FN1 CCL2 B2M
24 interstitial nephritis 30.6 UMOD REN B2M ALB
25 prostatitis 30.6 TGFB1 PTGS2 KLK3
26 polycystic kidney disease 30.6 REN MIR192 EGF AQP2 ALB
27 pyelonephritis 30.5 UMOD TGFB1 NAGLU CCL2 AQP2 ALB
28 cystadenocarcinoma 30.5 PIK3CA MIR199A1 B2M
29 renal fibrosis 30.5 TGFB1 REN MIR199A1 FN1 CCL2 ALB
30 uremia 30.5 REN B2M ALB
31 kidney disease 30.4 UMOD TGFB1 REN NAGLU MIR192 FN1
32 lymphocele 30.4 KLK3 ALB
33 pulmonary hypertension 30.4 REN PTGS2 FN1 CCL2 ALB
34 constipation 30.4 PTGS2 GGT1 GDNF ALB
35 pyuria 30.4 KLK3 B2M ALB
36 acute kidney tubular necrosis 30.4 UMOD REN NAGLU GGT1 B2M ALB
37 cystic kidney disease 30.3 UMOD REN MIR192 EGF B2M AQP2
38 diabetes mellitus 30.2 UMOD TGFB1 REN PTGS2 PIK3CA GGT1
39 myeloma, multiple 30.2 MIR199A1 FN1 EGF CCL2 B2M ALB
40 vascular disease 30.2 TGFB1 REN PTGS2 MIR199A1 FN1 CCL2
41 polycystic kidney disease 4 with or without polycystic liver disease 30.2 UMOD EGF AQP2
42 leukemia, acute myeloid 30.1 PIK3CA MIR199A1 FN1 EGF B2M ALB
43 renal cell carcinoma, nonpapillary 30.1 PIK3CA MIR199A1 MIR192 GGT1 EGF B2M
44 autosomal dominant polycystic kidney disease 30.0 TGFB1 REN MIR199A1 MIR192 EGF CCL2
45 urinary system disease 29.9 UMOD REN NAGLU MIR199A1 MIR192 KLK3
46 prostate cancer 29.8 TGFB1 PTGS2 PIK3CA MIR199A1 KLK3 HBEGF
47 neuroblastoma 29.7 PTGS2 PIK3CA GDNF FN1 EGF ALB
48 ovarian cancer 29.6 TGFB1 PTGS2 PIK3CA MIR199A1 KLK3 HBEGF
49 lower urinary tract obstruction, congenital 12.9
50 fetal lower urinary tract obstruction 12.7

Comorbidity relations with Urinary Tract Obstruction via Phenotypic Disease Network (PDN): (show all 19)


Acute Cystitis Acute Kidney Failure
Bladder Cancer Bladder Neck Obstruction
Decubitus Ulcer Deficiency Anemia
Familial Atrial Fibrillation Heart Disease
Hydronephrosis Kidney Disease
Nephrolithiasis, X-Linked Recessive, with Renal Failure Paralytic Ileus
Prostate Calculus Prostate Cancer
Prostatic Hypertrophy Prostatitis
Protein-Energy Malnutrition Ureterolithiasis
Urethral Stricture

Graphical network of the top 20 diseases related to Urinary Tract Obstruction:



Diseases related to Urinary Tract Obstruction

Symptoms & Phenotypes for Urinary Tract Obstruction

UMLS symptoms related to Urinary Tract Obstruction:


dysuria, polyuria, urgency of micturition, other and unspecified genitourinary symptoms, renal colic, pain in urethra, uti symptoms, urethral burning on micturition, loin pain, ureteral pain, flank tenderness, difficulty passing urine, urinary tenesmus, burning urination, bladder discomfort, renal pain, urologic problem

MGI Mouse Phenotypes related to Urinary Tract Obstruction:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 growth/size/body region MP:0005378 10.25 AQP2 B2M BNC2 EGF FN1 GDNF
2 cardiovascular system MP:0005385 10.21 ALB B2M FN1 GDNF HBEGF KLK3
3 immune system MP:0005387 10.18 ALB B2M CCL2 EGF FN1 GDNF
4 mortality/aging MP:0010768 10.07 ALB AQP2 B2M BNC2 FN1 GDNF
5 integument MP:0010771 10.02 AQP2 B2M EGF FN1 GGT1 HBEGF
6 muscle MP:0005369 9.81 ALB FN1 GDNF HBEGF KLK3 PIK3CA
7 renal/urinary system MP:0005367 9.61 ALB AQP2 GDNF GGT1 NAGLU PTGS2
8 reproductive system MP:0005389 9.32 AQP2 B2M EGF FN1 GDNF GGT1

Drugs & Therapeutics for Urinary Tract Obstruction

Drugs for Urinary Tract Obstruction (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 208)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Angiotensin II Approved, Investigational Phase 4 4474-91-3, 11128-99-7, 68521-88-0 172198
2
Alfuzosin Approved, Investigational Phase 4 81403-80-7 2092
3
leucovorin Approved Phase 4 58-05-9 6006 143
4
Scopolamine Approved, Investigational Phase 4 6533-68-2, 51-34-3 5184
5
Valsartan Approved, Investigational Phase 4 137862-53-4 60846
6
Hydroxychloroquine Approved Phase 4 118-42-3 3652
7
Mirabegron Approved Phase 4 223673-61-8 9865528
8
Bupivacaine Approved, Investigational Phase 4 2180-92-9, 38396-39-3 2474
9
Rocuronium Approved Phase 4 119302-91-9, 143558-00-3 441290
10
Iodine Approved, Investigational Phase 4 7553-56-2 807
11
Povidone Approved Phase 4 9003-39-8
12
Povidone-iodine Approved Phase 4 25655-41-8
13
Folic acid Approved, Nutraceutical, Vet_approved Phase 4 59-30-3 6037
14
Cimetropium Experimental, Investigational Phase 4 150521-16-7
15
Uric acid Investigational Phase 4 69-93-2 1175
16 Parasympatholytics Phase 4
17 Angiotensin II Type 1 Receptor Blockers Phase 4
18 Angiotensinogen Phase 4
19 Angiotensin Receptor Antagonists Phase 4
20 Giapreza Phase 4
21 Antihypertensive Agents Phase 4
22 Adrenergic Antagonists Phase 4
23 Adrenergic alpha-1 Receptor Antagonists Phase 4
24 Hematinics Phase 4
25 Antirheumatic Agents Phase 4
26 Micronutrients Phase 4
27 Trace Elements Phase 4
28 Vitamins Phase 4
29 Antioxidants Phase 4
30 Vitamin B Complex Phase 4
31 Nutrients Phase 4
32 Folate Phase 4
33 Vitamin B9 Phase 4
34 Gastrointestinal Agents Phase 4
35 Antiemetics Phase 4
36 Mydriatics Phase 4
37 Butylscopolammonium Bromide Phase 4
38 Interferon-alpha Phase 4
39 Antiparasitic Agents Phase 4
40 interferons Phase 4
41 Antiprotozoal Agents Phase 4
42 Immunoglobulin A Phase 4
43 Antimalarials Phase 4
44 Cholinergic Agents Phase 4
45 Cholinergic Antagonists Phase 4
46 Neurotransmitter Agents Phase 4
47 Adrenergic beta-Agonists Phase 4
48 Adrenergic Agents Phase 4
49 Solifenacin succinate Phase 4 242478-38-2
50 Adrenergic beta-3 Receptor Agonists Phase 4

Interventional clinical trials:

(show top 50) (show all 173)
# Name Status NCT ID Phase Drugs
1 Usefulness Of Flospan As A Premedication For Colonoscopy : A Randomized Double Blind Controlled Trial Unknown status NCT01842932 Phase 4 Phloroglucin;Cimetropium bromide;Placebo
2 Evaluation of the Effectiveness of Antibiotic Prophylaxis in Children With a History of Upper Urinary Tract Infections:a Multicentre Randomised Study Unknown status NCT00156546 Phase 4 antibiotic to reduce the recurrence of infection
3 The Efficacy of Alpha-blockers for Expulsion of Distal Ureteral Stones Unknown status NCT00451061 Phase 4 Alfuzosin;Tamsulosin
4 Periprocedural Administration of Folic Acid for Prevention of Contrast Induced Nephropathy in Patients Undergoing Coronary CTA/Angiography/Angioplasty Unknown status NCT02444013 Phase 4 Folic acid;Placebo
5 Does Hyoscine N-butylbromide Administered During Colonoscopy Increase the Polyp Detection Rate? a Randomized, Single Center, Double Blind, Placebo-controlled Study Unknown status NCT01609855 Phase 4 Hyoscine Butyl Bromide 20mg/2 ml i.v.;Saline 2 ml i.v.
6 Hydroxychloroquine Sulfate Alleviates Persistent Proteinuria in IgA Nephropathy:a Single Center Prospective Randomized Controlled Study Unknown status NCT02765594 Phase 4 Hydroxychloroquine Sulfate;Valsartan
7 A Long-Term, Open-Label, Prospective Phase IV Study to Assess the Safety and Efficacy of Nephoxil® in Subjects With End Stage Renal Disease (ESRD) on Dialysis Completed NCT03256838 Phase 4 Ferric Citrate
8 Interest of MR Urography in the Evaluation of Functional Consequences of Urinary Tract in Children and Adults Completed NCT00301470 Phase 4
9 Efficacy and Safety of Mirabegron Compared With Solifenacin in Treatment of Overactive Bladder Completed NCT03558919 Phase 4 Mirabegron 25mg;Solifenacin Succinate 5 MG
10 Efficacy of the Liposomal Bupivacaine for Postoperative Pain Control in Urologic Procedures Recruiting NCT02805504 Phase 4 Exparel;Marcaine
11 Does Depth of Neuromuscular Blockade (NMB) Affect Surgical Conditions and Postoperative Pain in Obese Patients Undergoing Robotic Surgery Recruiting NCT03591289 Phase 4 NMB with rocuronium bromide
12 A Randomized Trial of Betadine Bladder Irrigations vs. Standard of Care Prior to Indwelling Catheter Removal to Reduce Bacteriuria and Catheter-Associated Urinary Tract Infections Terminated NCT03447639 Phase 4 Povidone-iodine irrigation
13 The Effect of L-carnitine on the Prevention of Renal Scarring in Children With Acute Pyelonephritis Unknown status NCT02007889 Phase 3 L-carnitine
14 Oral Omega-3 for Reduction of Kidney Scar Due to Pyelonephritis in Children Unknown status NCT02192580 Phase 3 Omega-3
15 Assessment of Analgesic Efficacy of Intranasal Desmopressin in the Treatment of Acute Pain in Patients With Renal Colic Unknown status NCT01742689 Phase 3 Desmopressin intranasal spray;Placebo intranasal spray;Indomethacin suppository
16 Evaluation of the Efficacy of Tamsulosin (Alpha Blockers) Compared to Phloroglucinol in Improving JJ Ureteral Stent Tolerance. A Randomized Controlled Trial Completed NCT01061073 Phase 3 Omexel;spasfon
17 Tamsulosin Phase III Clinical Trial -Double-Blind, Placebo Controlled Study in Male Patients With Lower Urinary Tract Syndrome Completed NCT00239317 Phase 3 Tamusulosin
18 Tamsulosin Phase III Clinical Trial -Double-Blind, Placebo Controlled Study in Female Patients With Lower Urinary Tract Syndrome Completed NCT00239265 Phase 3 Tamuslosin
19 A Double-Blind, Randomized, Parallel Group, Multi-Centre Study to Evaluate the Efficacy and Safety of Mirabegron Compared to Solifenacin in Subjects With Overactive Bladder (OAB) Treated With Antimuscarinics and Dissatisfied Due to Lack of Efficacy Completed NCT01638000 Phase 3 Mirabegron;Solifenacin succinate
20 Efficacy and Tolerability of Propiverine Hydrochloride Extended Release (ER) Compared to Immediate Release (IR) in Patients With Neurogenic Detrusor Overactivity. A Randomized, Double Blind, Parallel Group, Multicenter Clinical Trial Completed NCT01530620 Phase 3 Propiverine hydrochloride ER (extended release);Propiverine hydrochloride IR (immediate release)
21 A Randomized, Double-Blind, Parallel-Group, Placebo- and Active-Controlled, Multi-center Study to Evaluate the Efficacy, Safety and Tolerability of Combinations of Solifenacin Succinate and Mirabegron Compared to Solifenacin Succinate and Mirabegron Monotherapy in the Treatment of Overactive Bladder Completed NCT01972841 Phase 3 Solifenacin succinate;Mirabegron;Placebo to match solifenacin succinate;Placebo to match mirabegron
22 An International Phase 3, Randomized, Double-Blind, Placebo- and Active (Tolterodine)-Controlled Multicenter Study to Evaluate the Safety and Efficacy of Vibegron in Patients With Symptoms of Overactive Bladder Completed NCT03492281 Phase 3 vibegron;Vibegron placebo;Tolterodine Tartrate ER;Tolterodine placebo
23 An International Phase 3, Randomized, Double-Blind, Active (Tolterodine)-Controlled Multicenter Extension Study to Evaluate the Long-Term Safety and Efficacy of Vibegron in Patients With Symptoms of Overactive Bladder Completed NCT03583372 Phase 3 Vibegron;placebos;Tolterodine Tartrate ER
24 A Randomized, Double-Blind, Placebo-Controlled, Multi-Center, Definitive Phase III Study of the Effects of Ferric Citrate on Serum Phosphate in Subjects With End Stage Renal Disease Completed NCT01503736 Phase 3 ferric citrate;ferric citrate;ferric citrate
25 A Randomized, Double-Blind, Parallel-Group, Active-Controlled, Multi-center Study to Evaluate the Long-Term Safety and Efficacy of Combination of Solifenacin Succinate With Mirabegron Compared to Solifenacin Succinate and Mirabegron Monotherapy in Subjects With Overactive Bladder Completed NCT02045862 Phase 3 Solifenacin succinate;Mirabegron;Placebo to match solifenacin;Placebo to match mirabegron
26 A Randomized, Double-Blind, Multi-Centre Study to Evaluate the Efficacy and Safety of Adding Mirabegron to Solifenacin in Incontinent OAB Subjects Who Have Received Solifenacin for 4 Weeks and Warrant Additional Relief for Their OAB Symptoms Completed NCT01908829 Phase 3 mirabegron 25 mg;mirabegron 50 mg;solifenacin 5 mg;solifenacin 10 mg;mirabegron 25 mg matching placebo;mirabegron 50 mg matching placebo;solifenacin 5 mg matching placebo;solifenacin 10 mg matching placebo
27 A Multicenter, Randomized Study To Compare The Safety And Efficacy Of Oral Levofloxacin With That Of Lomefloxacin HCl In The Treatment Of Complicated Urinary Tract Infections In Adults Completed NCT00258102 Phase 3 Levofloxacin
28 A Multicenter, Double-Blind, Randomized Study To Compare The Safety And Efficacy Of Oral Levofloxacin With That Of Ciprofloxacin HCl In The Treatment Of Complicated Urinary Tract Infections In Adults Completed NCT00258089 Phase 3 Levofloxacin
29 Saw Palmetto Extract In Benign Prostatic Hyperplasia Completed NCT00037154 Phase 3 Saw Palmetto
30 Self-management for Men With Uncomplicated Lower Urinary Tract Symptoms. A Randomised Controlled Trial Against Standard Therapy Completed NCT00270309 Phase 3
31 A Multicenter, Randomized, Open‐Label, Active‐Controlled, Parallel Study to Assess the Efficacy and Safety of Ferric Citrate Capsules for the Treatment of Hyperphosphatemia in Patients With Chronic Kidney Disease Undergoing Hemodialysis Recruiting NCT03984760 Phase 3 Ferric Citrate;Sevelamer Carbonate
32 Perioperative Pregabalin as Part of a Multimodal Treatment Plan for Pain After Ureteroscopy With Stent Placement: a Pilot Active, not recruiting NCT03927781 Phase 3 Pregabalin 300mg
33 An Open-Label Roll-Over Study to Evaluate the Long-Term Safety and Efficacy of DCR-PHXC Solution for Injection (Subcutaneous Use) in Patients With Primary Hyperoxaluria Enrolling by invitation NCT04042402 Phase 3 DCR-PHXC
34 A PHASE 3B, RANDOMIZED, OPEN-LABEL, MULTI-CENTER STUDY TO EVALUATE THE EFFICACY AND SAFETY OF MAINTENANCE THERAPY WITH VALRUBICIN VERSUS NO MAINTENANCE, IN SUBJECTS TREATED WITH VALRUBICIN INDUCTION FOR CARCINOMA IN SITU (CIS) OF THE BLADDER Terminated NCT01310803 Phase 3 VALSTAR - Maintenance Therapy
35 A Randomized Controlled Study Comparing Adjuvant Hyperthermia Treatment in Conjunction With Mitomycin C Versus BCG Immunotherapy (BCG) Adjuvant Treatment in Patients With Superficial Transitional Cell Carcinoma of the Bladder (STCCB) Terminated NCT00384891 Phase 3 Bacillus Calmette-Guérin
36 A Phase 3, Randomized, Active-Controlled, Open-Label, Multicenter Study to Evaluate the Efficacy and Safety of EN3348 (MCC) as Compared With Mitomycin C in the Intravesical Treatment of Subjects With BCG Recurrent or Refractory Non-Muscle Invasive Bladder Cancer Terminated NCT01200992 Phase 3
37 A Multi-Centre, Randomised, Open-Label Active-Controlled Study Comparing Safety and Efficacy of Synergo Radiofrequency (RF)-Induced Hyperthermia-Chemotherapy With Mitomycin C (RITE) Versus Bacillus Calmette-Guérin (BCG) as First-Line Treatment of Non-Muscle Invasive Papillary Bladder Cancer (NMIBC) Withdrawn NCT02254915 Phase 3 Bacillus Calmette-Guérin
38 Randomized Controlled Trial of Fetal Cystoscopy Versus Vesico-amniotic Shunting in Severe Lower Urinary Tract Obstructions Unknown status NCT01552824 Phase 2
39 A Randomised Trial of Prednisone and Tamoxifen in Patients With Idiopathic Retroperitoneal Fibrosis Unknown status NCT00440349 Phase 2 Tamoxifen;Prednisone
40 A Randomized, Double-Blind, Factorial, Parallel-Group, Active and Placebo-Controlled, Multicenter Dose-Ranging Study to Evaluate the Efficacy, Safety and Tolerability of Six Dose Combinations of Solifenacin Succinate and Mirabegron Compared to Mirabegron and Solifenacin Succinate Monotherapies in the Treatment of Overactive Bladder. Completed NCT01340027 Phase 2 Mirabegron;Solifenacin succinate;Placebo
41 A Multicenter, Single-Arm Study of the Effects of Atrasentan on Spermatogenesis and Testicular Function Completed NCT02118714 Phase 2 Atrasentan
42 RTA 402 Phase 2 Clinical Trial (A Randomized, Double-blind, Placebo-controlled Clinical Trial in Patients With Chronic Kidney Disease and Type 2 Diabetes) Completed NCT02316821 Phase 2 RTA 402;Placebo
43 Muscle Cell Mediated Therapy for Stress Urinary Incontinence in Males Following Prostate Surgery: An Investigation of Cook MyoSite Autologous Muscle Derived Cells Completed NCT02291432 Phase 1, Phase 2
44 A Phase 2, Randomized, Double-blind, Placebo-controlled, Parallel Group, Adaptive, Combined Proof of Concept and Dose-Finding Study to Investigate Efficacy, Safety, Pharmacodynamics and Pharmacokinetics of ASP3652 in the Treatment of Female Patients With Bladder Pain Syndrome / Interstitial Cystitis Completed NCT01613586 Phase 2 ASP3652;Placebo
45 Evaluation of the Safety of Pre-TURBT Intravesical Instillation of Escalating Doses of TC-3 Gel Mixed With Mitomycin C (MMC) in Non-muscle Invasive Bladder Cancer (NMIBC) Patients Completed NCT02307487 Phase 2 120 mg MMC in 90ml gel;140 mg MMC in 90ml gel;160 mg MMC in 90ml gel;120 mg MMC in 60ml gel;140 mg MMC in 60ml gel;160 mg MMC in 60ml gel
46 A Phase II, Randomized, Active Comparator-Controlled Clinical Trial to Study the Safety, Tolerability, and Efficacy of MK-7655 + Imipenem/Cilastatin Versus Imipenem/Cilastatin Alone in Patients With Complicated Urinary Tract Infection (cUTI) Completed NCT01505634 Phase 2 Relebactam 250 mg;Relebactam 125 mg;imipenem/cilastatin 500 mg;Placebo to relebactam;Ciprofloxacin
47 A Phase 2 Placebo-Controlled, Double-Blind, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of DCR-PHXC Solution for Injection (Subcutaneous Use) in Patients With Primary Hyperoxaluria Recruiting NCT03847909 Phase 2 DCR-PHXC;Sterile Normal Saline (0.9% NaCl)
48 A Phase 1/2a Pilot Study of Intravesical TSD-001 for Treatment of Low-Grade, Stage Ta, Non Muscle Invasive Bladder Cancer Recruiting NCT03081858 Phase 1, Phase 2 TSD-001
49 Efficacy of the Oncoxin-Viusid® Nutritional Supplement on the Quality of Life of Patients With Advanced or Metastatic Ovarian Epithelial Cancer. Clinical Trial Phase II. Recruiting NCT03562897 Phase 2
50 A Phase 2, Multicenter, Open-Label, Extension Study to Evaluate the Long-Term Administration of ALN-GO1 in Patients With Primary Hyperoxaluria Type 1 Active, not recruiting NCT03350451 Phase 2 Lumasiran

Search NIH Clinical Center for Urinary Tract Obstruction

Genetic Tests for Urinary Tract Obstruction

Anatomical Context for Urinary Tract Obstruction

MalaCards organs/tissues related to Urinary Tract Obstruction:

40
Kidney, Prostate, Testes, Brain, Bone, Neutrophil, Cervix

Publications for Urinary Tract Obstruction

Articles related to Urinary Tract Obstruction:

(show top 50) (show all 3842)
# Title Authors PMID Year
1
New paradigms for advanced prostate cancer. 61 54
17554403 2007
2
Survival of patients with hormone refractory prostate cancer in the prostate specific antigen era. 61 54
15017212 2004
3
Glial cell line derived neurotrophic factor is expressed by epithelia of human renal dysplasia. 54 61
12441997 2002
4
[Urinary enzyme excretion in childhood uropathy]. 61 54
12434629 2002
5
[Screening for early detection of prostate cancer (first experience in Israel)]. 54 61
11242898 2001
6
Heparin-binding EGF-like growth factor expression increases selectively in bladder smooth muscle in response to lower urinary tract obstruction. 61 54
10576204 1999
7
Clinical pharmacokinetics and pharmacodynamics of finasteride. 54 61
8846625 1996
8
Tamm-Horsfall protein: are serum levels a marker for urinary tract obstruction? 61 54
7696106 1994
9
[Evaluation of renal function and prediction of renal functional recovery in children with unilateral hydronephrosis using renal pelvic urine]. 54 61
1282579 1992
10
Bilateral ureteric re-implant for an 18 months old boy with a huge bilateral hutch diverticulum presented with recurrent urinary retention. 61
32322530 2020
11
Antenatal intervention for congenital fetal lower urinary tract obstruction (LUTO): a systematic review and meta-analysis. 61
30501534 2020
12
Clinical predictors of chronic kidney disease in congenital lower urinary tract obstruction. 61
31197474 2020
13
Prenatal diagnosis of complete penoscrotal transposition with normal scrotum: Two case reports and review of the literature. 61
32319694 2020
14
Obstructive uropathy and unexpected death. 61
31642011 2020
15
[Benign prostatic hyperplasia management during COVID-19 pandemia.] 61
32538810 2020
16
Effect of α-1-adrenolytic agent and 5-α-reductase inhibitor on renal function in an experimental model of hyperprolactinemia-induced benign prostatic hyperplasia. 61
32564045 2020
17
Renal disorders in rheumatologic diseases: the spectrum is changing (part 2. Arthridides). 61
32548773 2020
18
Fetal anesthesia: intrauterine therapies and immediate postnatal anesthesia for noncardiac surgical interventions. 61
32324666 2020
19
Nondilated Obstructive Uropathy - Still Underappreciated. 61
32504684 2020
20
Fetal lower urinary tract obstruction: What should we tell the prospective parents? 61
32065667 2020
21
Retrospective Analysis of the Role of Antibiotic Prophylaxis in the Placement and Replacement of Percutaneous Nephrostomy Catheters in Patients with Malignant Ureteral Obstruction. 61
31800348 2020
22
Towards data-driven medical imaging using natural language processing in patients with suspected urolithiasis. 61
32172185 2020
23
[Relevance of clinical and serum parameters on severe urinary sepsis after renal obstruction.] 61
32379060 2020
24
Longitudinal kidney injury biomarker trajectories in children with obstructive uropathy. 61
32444926 2020
25
Urine drainage management in colorectal surgery. 61
32446914 2020
26
Evaluation of dynamic thiol-disulphide homeostasis in obstructive uropathy. 61
31955364 2020
27
ACR Appropriateness Criteria® Radiologic Management of Urinary Tract Obstruction. 61
32370972 2020
28
Renal elasticity and perfusion changes associated with fibrosis on ultrasonography in a rabbit model of obstructive uropathy. 61
31858205 2020
29
Immune Checkpoint Inhibitor-induced Fanconi Syndrome. 61
32431966 2020
30
Case report: IgG4-related renal disease co-existing with retroperitoneal fibrosis. 61
32420186 2020
31
Bilateral aniridia and congenital ureteral valve: Role of genetic testing. 61
32056389 2020
32
Rare giant inguinal hernia causing end-stage dialysis-dependent renal failure. 61
32300033 2020
33
Etiology and management of early pregnancy renal anhydramnios: Is there a place for serial amnioinfusions? 61
32003482 2020
34
Nephrotoxicity in cancer treatment: An overview. 61
32355641 2020
35
Renal salvage, an achievable goal in patients with emphysematous pyelonephritis: Outcomes of an algorithmic renal preserving strategy. 61
32565654 2020
36
When the Good Old X Ray Saved the Day. 61
32315690 2020
37
Anterior urethral valves - A rare but challenging congenital pathology. 61
32340880 2020
38
Quantifying the forces needed for ureteral stent removal: Initial evaluation of magnetic stent removal devices on benchtop and porcine models. 61
32340884 2020
39
Fetal therapies as standard prenatal care in Japan. 61
32206649 2020
40
Impact of successful pediatric ureteropelvic junction obstruction surgery on urinary HIP/PAP and BD-1 levels. 61
32278658 2020
41
Frequency of urinary tract infection in children with antenatal diagnosis of urinary tract dilatation. 61
31462436 2020
42
Neurodevelopmental Outcome in Infants with Lower Urinary Tract Obstruction Based on Different Degrees of Severity. 61
32146466 2020
43
Recent advances in chronic granulomatous disease. 61
32181279 2020
44
Presepsin and procalcitonin as predictors of sepsis based on the new Sepsis-3 definitions in obstructive acute pyelonephritis. 61
32160878 2020
45
Eighteen-Year Review of Resident Performance on the American Urological Association In-Service Examination. 61
31785278 2020
46
Delayed Presentation of Urinoma Following Renal Transplant Biopsy: A Case Report. 61
32143757 2020
47
[The results of treatment of newborns with postrenal anuria due to upper urinary tract obstruction, caused by fungal bezoar]. 61
32191007 2020
48
Prenatal Diagnosis of Megacystitis and Hydronephrosis in an Equine Fetus: How Transabdominal Ultrasonography Can Help to Diagnose Fetal Abnormalities. 61
31952643 2020
49
[Native kidney ultrasound in obstructive uropathy]. 61
32068358 2020
50
Re: Common Clinical Markers Predict End-Stage Renal Disease in Children with Obstructive Uropathy. 61
31710546 2020

Variations for Urinary Tract Obstruction

Expression for Urinary Tract Obstruction

Search GEO for disease gene expression data for Urinary Tract Obstruction.

Pathways for Urinary Tract Obstruction

Pathways related to Urinary Tract Obstruction according to GeneCards Suite gene sharing:

(show all 18)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.91 TGFB1 REN PTGS2 HBEGF EGF CCL2
2 12.68 TGFB1 PTGS2 PIK3CA KLK3 FN1 EGF
3
Show member pathways
12.39 TGFB1 PTGS2 PIK3CA HBEGF GDNF FN1
4
Show member pathways
12.2 PTGS2 GGT1 CCL2 ALB
5 12.17 TGFB1 PIK3CA HBEGF FN1
6
Show member pathways
12 TGFB1 PIK3CA MIR199A1 EGF
7 11.84 TGFB1 PTGS2 GDNF CCL2
8 11.76 TGFB1 PTGS2 FN1 CCL2
9 11.72 PTGS2 PIK3CA FN1
10
Show member pathways
11.67 TGFB1 PIK3CA KLK3 HBEGF EGF
11 11.62 TGFB1 PIK3CA FN1 CCL2
12 11.54 TGFB1 HBEGF FN1 EGF
13 11.51 TGFB1 EGF CCL2
14 11.49 KLK3 HBEGF FN1
15
Show member pathways
11.42 TGFB1 PIK3CA HBEGF EGF
16 11.41 TGFB1 REN PTGS2 CCL2
17 11.38 TGFB1 PIK3CA FN1
18 10.94 PIK3CA HBEGF CCL2

GO Terms for Urinary Tract Obstruction

Cellular components related to Urinary Tract Obstruction according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular exosome GO:0070062 9.91 UMOD NAGLU KLK3 GGT1 FN1 EGF
2 extracellular region GO:0005576 9.9 UMOD TGFB1 REN KLK3 HBEGF GDNF
3 extracellular space GO:0005615 9.47 UMOD TGFB1 REN MIR199A1 MIR192 KLK3
4 platelet alpha granule lumen GO:0031093 9.26 TGFB1 FN1 EGF ALB

Biological processes related to Urinary Tract Obstruction according to GeneCards Suite gene sharing:

(show all 14)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of cell proliferation GO:0008284 9.91 TGFB1 PTGS2 HBEGF GDNF FN1 EGF
2 cytokine-mediated signaling pathway GO:0019221 9.8 TGFB1 PTGS2 PIK3CA FN1 CCL2
3 cellular protein metabolic process GO:0044267 9.78 KLK3 FN1 B2M ALB
4 positive regulation of peptidyl-tyrosine phosphorylation GO:0050731 9.71 TGFB1 HBEGF EGF
5 response to organic substance GO:0010033 9.7 TGFB1 REN PTGS2
6 positive regulation of peptidyl-serine phosphorylation GO:0033138 9.67 TGFB1 PTGS2 PIK3CA
7 platelet degranulation GO:0002576 9.67 TGFB1 FN1 EGF ALB
8 MAPK cascade GO:0000165 9.65 TGFB1 HBEGF GDNF EGF CCL2
9 protein kinase B signaling GO:0043491 9.63 TGFB1 PIK3CA CCL2
10 angiogenesis GO:0001525 9.55 PTGS2 PIK3CA FN1 EGF CCL2
11 positive regulation of epidermal growth factor-activated receptor activity GO:0045741 9.51 HBEGF EGF
12 ERBB2 signaling pathway GO:0038128 9.5 PIK3CA HBEGF EGF
13 positive regulation of protein kinase B signaling GO:0051897 9.35 TGFB1 PIK3CA MIR199A1 HBEGF EGF
14 epidermal growth factor receptor signaling pathway GO:0007173 8.92 TGFB1 PIK3CA HBEGF EGF

Molecular functions related to Urinary Tract Obstruction according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 growth factor activity GO:0008083 8.92 TGFB1 HBEGF GDNF EGF

Sources for Urinary Tract Obstruction

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....